Brought to you by 
Indevus, Pliva co-promote Sanctura in €161.3mm deal
22 Jul 2004
Executive Summary
In a deal potentially worth €161.3mm ($195mm), Indevus Pharmaceuticals has licensed specialty pharmaceuticals company Pliva DD exclusive US co-promotion rights to sell--through Pliva's US subsidiary Odyssey Pharmaceuticals--Sanctura (trospium chloride) to treat overactive bladder (OAB), an urge incontinence disorder.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Indevus, Pliva co-promote Sanctura in €161.3mm deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice